tbuckley/cabot-search huggingface dataset:
Kindness Matters: A Randomized Controlled Trial of a Mindful Self-Compassion Intervention Improves Depression, Distress, and HbA1c Among Patients With Diabetes
Authors: Anna M. Friis, Malcolm H. Johnson, Richard G. Cutfield, Nathan S. Consedine
Journal: Diabetes Care (2016)

OBJECTIVE Mood difficulties are common among patients with diabetes and are linked to poor blood glucose control and increased complications. Evidence on psychological treatments that improve both mood and metabolic outcomes is limited. Greater self-compassion predicts better mental and physical health in both healthy and chronically ill populations. Thus, the purpose of this randomized controlled trial (RCT) was to evaluate the effects of self-compassion training on mood and metabolic outcomes among patients with diabetes. RESEARCH DESIGN AND METHODS This RCT tested the effects of a standardized 8-week mindful self-compassion (MSC) program (n = 32) relative to a wait-list control condition (n = 31) among patients with type 1 and type 2 diabetes. Measures of self-compassion, depressive symptoms, diabetes-specific distress, and HbA1c were taken at baseline (preintervention), at week 8 (postintervention), and at 3-month follow-up. RESULTS Repeated-measures ANOVA using intention to treat showed that MSC training increased self-compassion and produced statistically and clinically significant reductions in depression and diabetes distress in the intervention group, with results maintained at 3-month follow-up. MSC participants also averaged a clinically and statistically meaningful decrease in HbA1c between baseline and follow-up of &amp;gt;10 mmol/mol (nearly 1%). There were no overall changes for the wait-list control group. CONCLUSIONS This initial report suggests that learning to be kinder to oneself (rather than being harshly self-critical) may have both emotional and metabolic benefits among patients with diabetes.
Abstract 2307: Contemporary Perioperative Results of Isolated Aortic Valve Replacement for Aortic Stenosis: Implications for Transcatheter Aortic Valve Implantation
Authors: S C Malaisrie, Patrick M McCarthy, Edwin C McGee, Richard Lee, Vera Rigolin, Charles J Davidson, Nalini M Rajamannan, Robert O Bonow
Journal: Circulation (2008)

Transcatheter aortic valve implantation (AVI) is compelling for some high-risk patients with aortic stenosis (AS). However, comparison of procedure outcomes with older surgical series may overestimate operative risk. We therefore analyzed our contemporary series of isolated aortic valve replacement (AVR) for AS. From April 2004 to January 2008, 642 patients underwent AVR with or without concomitant cardiac procedures. Of these patients, 175 patients had an isolated AVR, and 140 patients underwent isolated AVR for AS. The characteristics were age 68, male gender 56%, ejection fraction 57%. Sixty-four percent had a minimally-invasive AVR and 18% were reoperations. Twenty percent were 80 years old or greater, 35% were in NYHA functional class III-IV, and 4% had an estimated operative mortality of 10% or greater using the Society of Thoracic Surgery (STS) risk calculator. Thirty-day mortality was 0%, but there was one in-hospital death (0.7%) from complications of an esophageal perforation. Reoperation for bleeding occurred in 5.7%, cerebrovascular accident (CVA) in 0%, acute renal failure (ARF) in 2.9%, myocardial infarction (MI) in 0%. Bioprosthetic valves were used in 98.6% and mechanical in 1.4%. Mean gradient decreased from 48 mmHg to10 mmHg. Actuarial survival was 97% and 90% at 1 and 3 years. Patients &gt;80 years (n=28) were more likely to have an increased length of hospital stay (9.8 versus 6.3 days, p=0.01) and less likely to be discharged to home (48% versus 86%, p&lt;0.01) as compared to patients &lt;80 years. Today, AVR for AS can be performed in many high-risk patients with low operative mortality and morbidity, although patients over 80 years are at greater risk of prolonged recovery. Transcatheter AVI should be compared to this high threshold.
SSB1/NABP2 and SSB2/NABP1 Have Essential and Overlapping Roles in Maintaining Hematopoietic Stem and Progenitor Cells
Authors: Wei Shi, Therese Vu, Glen Boyle, Fares Al-Ejeh, Tej Pandita, Krzysztof Ginalski, Maga Rowicka, Steven W. Lane, Kum Kum Khanna
Journal: Blood (2015)
Herpes Zoster
Authors: A G Kulkarni, N S Brid
Journal: New England Journal of Medicine (1995)

Figure 1. Confluent vesicular lesions of herpes zoster in consecutive dermatomes are visible in two distinct locations in a 20-year-old man with miliary tuberculosis. The patient was being treated with four antitubercular drugs; he also received prednisolone (1 mg per kilogram of body weight per day) because meningeal involvement was suspected. The lesions, accompanied by severe pain, appeared 4 weeks after therapy was begun and healed within 10 days after prednisolone was discontinued. Except for the prednisolone, the patient had no known cause of immunosuppression. He was seronegative for the human immunodeficiency virus. The miliary tuberculosis was cured by drug . . .
In Primary Aldosteronism, Mineralocorticoids Influence Exosomal Sodium-Chloride Cotransporter Abundance
Authors: Martin J. Wolley, Aihua Wu, Shengxin Xu, Richard D. Gordon, Robert A. Fenton, Michael Stowasser
Journal: Journal of the American Society of Nephrology (2016)

Distal tubular sodium retention is a potent driver of hypertension, and the thiazide–sensitive sodium-chloride cotransporter (NCC) has a key role in this process. In humans, factors regulating NCC are unclear, but in animal models, aldosterone is a potent regulator, possibly via effects on plasma potassium. We studied the effects of the mineralocorticoid fludrocortisone on the abundance of NCC and its phosphorylated form (pNCC) as well as WNK lysine deficient protein kinase 4 (WNK4) and STE20/SPS1–related, proline alanine–rich kinase (SPAK) in human urinary exosomes. We isolated exosomes from daily urine samples in 25 patients undergoing fludrocortisone suppression testing (100 μ g every 6 hours for 4 days) to diagnose or exclude primary aldosteronism. Over the course of the test, NCC levels increased 3.68-fold ( P &lt;0.01) and pNCC levels increased 2.73-fold ( P &lt;0.01) relative to baseline. The ratio of pNCC/NCC dropped by 48% ( P &lt;0.01). The abundance of WNK4 increased 3.23-fold ( P &lt;0.01), but SPAK abundance did not change significantly ( P =0.14). Plasma potassium concentration strongly and negatively correlated with pNCC, NCC, and WNK4 abundance ( P &lt;0.001 for all). This study shows that, in humans, mineralocorticoid administration is associated with a rapid increase in abundance of NCC and pNCC, possibly via the WNK pathway. These effects may be driven by changes in plasma potassium.
In Vivo Antigenic Modification of Tumor Cells. III. Metastatic Thymic Lymphoma Specifically Infected by Thymotropic Retrovirus&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="FN3"&gt;3&lt;/xref&gt;
Authors: J D Iglehart, K J Weinhold, G Huper, K Thiel, D P Bolognesi
Journal: JNCI Journal of the National Cancer Institute (1981)

Tissue distribution of radiation leukemia virus (RadLV) was examined after its inoculation into normal C57BL/6J (B6) mice, B6 mice bearing a transplantable, non-virus-producing thymic lymphoma (RL12-NP), and B6 mice bearing a transplanted non-virus producing, Harvey murine sarcoma virus-transformed fibrosarcoma. Virus expression was determined by competition radioimmunoassay for murine leukemia virus (MuLV) p30 (predominant group-reactive antigen of MuLV) and for RadLV p12 (a highly type-specific MuLV polypeptide) and by membrane immunofluorescence for cell surface gp71 (predominant envelope glycoprotein of MuLV). Normal adult B6 mice were given three sequential iv injections of RadLV and were examined several times up to 200 days later for the appearance of neoplastic disease or expression of virion antigens. No clinical abnormalities were noted, and animals remained healthy for greater than 200 days. Significant levels of MuLV p30 and RadLV p12 were detected only in the thymuses. Organs and tumors from RL12-NP-inoculated animals contained low or nondetectable levels of virion antigens. Inoculation of mice with RL12-Rad, a cell line derived by in vitro infection of RL12-NP cells with RadLV, produced widespread, discrete metastatic tumors and infiltrated the lymphoid organs of B6 mice in a pattern identical to that observed after administration of RL12-NP cells. Lymphoid organs of RL12-Rad-inoculated animals expressed variable levels of virion antigens reflecting differences in the extent of tumor cell infiltration as opposed to virus spread from tumor to host cells. Administration of infectious RadLV systemically into RL12-NP tumor-bearing animals converted these tumors to viron antigen expressors with levels in superinfected tumors equivalent to those found in RL12-Rad-induced tumors. Infection was highly selective, and host tissues were minimally contaminated by the inoculated virus. Part of this selectivity was explained by the thymotropic property of RadLV. A rapidly dividing murine fibrosarcoma was not infected by RadLV, but this same non-virus-expressing tumor could be infected by common fibrotropic MuLV isolates.
Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics
Authors: Pamela Thompson, Ryan Fleming, Binyam Bezabeh, Fengying Huang, Shenlan Mao, Cui Chen, Jay Harper, Haihong Zhong, Xizhe Gao, Xiang-Qing Yu, Mary Jane Hinrichs, Molly Reed, Adeela Kamal, Patrick Strout, Song Cho, Rob Woods, Robert E. Hollingsworth, Rakesh Dixit, Herren Wu, Changshou Gao, Nazzareno Dimasi
Journal: Journal of Controlled Release (2016)
Sequential Brief Chemo-Immunotherapy FND + Rituximab in Elderly Patients with Advanced Stage Follicular Lymphoma (FL): High Clinical and Molecular Remission Rate Associated with a Prolonged Failure-Free Survival.
Authors: Umberto Vitolo, Carola Boccomini, Marco Ladetto, Enrico Pogliani, Delia Rota Scalabrini, Corrado Tarella, Claudia Castellino, Massimo Aglietta, Monica Astolfi, Andrea Carpaneto, Paolo Corradini, Antonella Darbesio, Alberto De Crescenzo, Alessandro Levis, Anna Marina Liberati, Sergio Morandi, Lorella Orsucci, Patrizia Pregno, Luigi Rigacci, Fausto Rossini, Anna Tonso, Eugenio Gallo
Journal: Blood (2004)
Physicochemical Studies of Reversible and Irreversible Complexes of Cobalt, Histidine, and Molecular Oxygen
Authors: John Z. Hearon, Dean Burk, Arthur L. Schade
Journal: JNCI Journal of the National Cancer Institute (1949)

Physicochemical Studies of Reversible and Irreversible Complexes of Cobalt, Histidine, and Molecular Oxygen Get access John Z. Hearon, John Z. Hearon Search for other works by this author on: Oxford Academic PubMed Google Scholar Dean Burk, Dean Burk National Cancer Institute, National Institutes of Health, Public Health Service, Federal Security Agency Search for other works by this author on: Oxford Academic PubMed Google Scholar Arthur L. Schade Arthur L. Schade Overly Biochemical Research Foundation, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 9, Issue 4, February 1949, Pages 337–377, https://doi.org/10.1093/jnci/9.4.337 Published: 01 February 1949 Article history Received: 12 August 1947 Published: 01 February 1949
Case 9-1972
Authors: Richard C. Cabot, Benjamin Castleman, Robert E. Scully, Betty U. McNeely, Gordon S. Myers, Benjamin Castleman
Journal: New England Journal of Medicine (1972)

Presentation of CaseA 44-year-old man was admitted to the hospital because of dyspnea.He was known to have a murmur since early childhood but had enjoyed excellent health until two and a half years before admission, when exertional dyspnea developed, accompanied by anterior chest pain that was relieved by nitroglycerin. Twenty-eight months before entry he was admitted to another hospital for three weeks because of acute myocardial infarction. Thereafter he had persistent exertional dyspnea that progressed to dyspnea at rest, together with intermittent ankle edema, two-pillow orthopnea and paroxysmal nocturnal dyspnea several times nightly. The chest pain became more . . .
Haplo+cord transplantation: Neutrophil and platelet recovery and long-term survival compared to double umbilical cord blood (UCB) transplantation—A case-cohort analysis.
Authors: Koen Van Besien, Andrew S. Artz, Mei-Jie Zhang, Melissa Cushing, Amittha Wickrema, Sandra Korman, Hongtao Liu, Usama Gergis, Wendy Stock, Sebastian Alexander Mayer, Michael Russell Bishop, Tsiporah Shore, Richard A. Larson, Parameswaran Hari
Journal: Journal of Clinical Oncology (2014)

7004 Background: Double UCB (dUCB) SCT can result in long-term survival and low rates of chronic GVHD. Limitations are delayed engraftment and early TRM. We previously reported that co-infusion of CD34-selected SCT from a haplo-identical relative, with a single UCB graft (haplo+cord ) results in rapid count recovery and durable engraftment from the UCB graft. In the current study we compared the outcomes of haplo+cord to dUCB transplantation. Methods: As of October 2013, 99 pts have been treated with haplo+cord at two institutions. Their outcomes were compared with those of 737 adults undergoing dUCB during the same period and reported to CIBMTR. Haplo-cord pts were older, more of minority descent, and had higher risk disease. Haplo+cord cases were matched to 4 dUCB controls based on age, gender, race, disease type, disease stage pre-transplant, KPS and year of transplant. The final control group had 344 pts. Despite matching, a higher percentage of haplo+cord pts had high-risk disease, (44% vs 34%, p=0.06). Results: In multivariate analysis, engraftment of neutrophils and platelets was faster after haplo+cord than after dUCB SCT. By day 30, 91% of haplo-cord pts had neutrophil recovery (median 12 d) and 53% had platelet recovery (median 24 d) vs 72% (median 21 d) and 6% (median 45 d) of dUCB respectively (P<0.0001). Haplo+cord survival was superior at all time points (Table). At 4 years, 43% of haplo+cord pts were alive vs 21% of dUCB (p=0.0053). Conclusions: Haplo+cord results in much faster engraftment than dUCB transplantation. The trend toward improved survival, that becomes more significant with prolonged follow up, justifies further prospective studies. Event Haplo-cord (n=99) P1 dUCB (n=344) P2 P ANC recovery 30 Day 60 Day 90 Day 120 Day 91 % 96 % 96% 96 % 72 % 86 % 87 % 87 % <0.0001 0.0001 0.0001 0.0001 Platelet recovery 30 Day 60 Day 90 Day 120 Day 53% 75 % 79 % 80 % 6 % 54 % 64 % 66 % <0.0001 <0.0001 0.0014 0.0019 Overall survival 1 Year 2 Year 3 Year 4 Year 52 % 43 % 43 % 43 % 44 % 38 % 33 % 21 % 0.2277 0.3846 0.1219 0.0053
126O A phase I study evaluating the safety, efficacy, pharmacokinetics and pharmacodynamics of AL3810 in advanced solid tumors
Authors: J. Cao, J. Li, D. Ji, W. Shen, L. Jiang, X. Ma, J. Pang, A. Kanehisa, F. Legrand, A. Pallis, G. Paux, R. Robert, X. Chen, P. Letecheur, L. Qiang, J. Ding
Journal: Annals of Oncology (2015)
Induction of Hepatomas in Strain C3H Mice with 4-&lt;italic&gt;o&lt;/italic&gt;-Tolylazo-&lt;italic&gt;o&lt;/italic&gt;-Toluidine and Carbon Tetrachloride
Authors: Howard B. Andervont
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article Induction of Hepatomas in Strain C3H Mice with 4-o-Tolylazo-o-Toluidine and Carbon Tetrachloride Get access Howard B. Andervont Howard B. Andervont Laboratory of Biology, National Cancer Institute,2Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 2, February 1958, Pages 431–438, https://doi.org/10.1093/jnci/20.2.431 Published: 01 February 1958 Article history Received: 26 September 1957 Published: 01 February 1958
Extensive bone infarct in myeloid leukemia correlation of bone scan and magnetic resonance imaging.
Authors: W. EDDIE LAU, STEPHEN STUCKEY, VICTOR KALFF
Journal: Clinical Nuclear Medicine (2001)

EDDIE LAU, W. F. M.B.B.S., F.R.A.N.Z.C.R.; STUCKEY, STEPHEN F.R.A.N.Z.C.R., M.MED.; KALFF, VICTOR F.R.A.C.P. Author Information
Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.
Authors: Elizabeth R. Plimack, Joaquim Bellmunt, Shilpa Gupta, Raanan Berger, Robert B. Montgomery, Karl Heath, Jonathan Juco, Kenneth Emancipator, Kumudu Pathiraja, Jared K. Lunceford, Rodolfo F. Perini, Peter H. O'Donnell
Journal: Journal of Clinical Oncology (2015)

4502 Background: Pembrolizumab, an anti–PD-1 antibody, demonstrated antitumor activity and acceptable safety in patients with recurrent or metastatic PD-L1–positive urothelial cancer enrolled in the phase 1b KEYNOTE-012 study (NCT01848834). We present updated efficacy and safety data for these patients, as well as an analysis of the relationship between PD-L1 expression and ORR. Methods: Eligible patients had recurrent, metastatic, or persistent urothelial cancer of the bladder, renal pelvis, ureter, or urethra. Patients received pembrolizumab 10 mg/kg every 2 weeks until complete response, progression, or unacceptable toxicity. PD-L1 expression was evaluated in baseline tumor samples at a central laboratory. Patients were enrolled if there were ≥1% PD-L1–positive cells in tumor nests or a PD-L1–positive band in stroma by a prototype immunohistochemistry assay. Samples were also analyzed with the clinical trial immunohistochemistry assay. Response was evaluated every 8 weeks per RECIST v1.1 by central review. Results: Thirty-three patients were enrolled (median age, 70 years; ≥3 prior therapies, 33%; visceral or osseous metastases, 66%). Median follow-up duration was 13 months (range, 1-16). Grade 3-4 drug-related adverse events occurred in 5 (15%) patients. In the 28 patients with measurable disease at baseline, ORR was 25% (95% CI 11-45), with 3 (11%) complete and 4 (14%) partial responses per central review. At the time of analysis, median duration of response had not been reached (range, 16-50+ weeks). The 12-month PFS rate was 19%. ORR in patients with tumors positive for PD-L1 expression as assessed with the clinical trial assay was 38%. Conclusions: Pembrolizumab demonstrates durable antitumor activity in patients with advanced urothelial cancer. A higher response rate was seen in patients with PD-L1 expression. Further analysis of the relationship between response and predictive biomarkers is ongoing. Clinical trial information: NCT01848834.
Gene Therapy for Heart Failure: Back to the Bench
Authors: Seppo Ylä-Herttuala
Journal: Molecular Therapy (2015)

Gene therapy for heart failure hit another bump on the road to clinical translation with the announcement by Celladon that its lead product Mydicar'adeno-associated viral vector 1 (AAV1)-expressing sarcoplasmic reticulum calcium ATPase (SERCA2a)'had failed in the phase IIb CUPID2 trial.1 SERCA2a's role in heart failure was validated in the 1990s but proved to be an elusive target for therapeutic intervention using traditional drug discovery methods. It is well established that SERCA2a, which is critical to calcium homeostasis in the myocardium, is downregulated in failing heart, making it an important target for therapy.
Notes from the Field: Outbreak of Hand, Foot, and Mouth Disease Caused by Coxsackievirus A6 Among Basic Military Trainees — Texas, 2015
Authors: Jonathan Banta, Brittany Lenz, Mary Pawlak, Kelly Laskoski, Caitlin Seykora, Bryant Webber, Heather Yun, Simon Ritchie,
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

On July 7, 2015, a man aged 22 years reported to sick call during basic military training at Lackland Air Force Base (AFB), Texas. He had erythematous, crusted papulovesicular lesions on the extensor surfaces of the upper and lower extremities. The patient was afebrile and otherwise well, and was evaluated later that day by the dermatology service. A viral infection was considered most likely because of the patient's age, absence of fever or constitutional symptoms, and the distribution and morphology of the lesions. The initial differential diagnosis included Henoch-Schönlein purpura, parvovirus B19, and Rocky Mountain spotted fever. However, the clinical signs, including the unique morphology and distribution of grouped vesicles and papules was suggestive of hand, foot, and mouth disease (HFMD), although the patient did not have oral lesions and reported no contact with another person with HFMD. A viral culture and punch biopsy of one of the lesions were obtained.
<i>The Porch</i>
Authors: Thomas B. Cole
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Resolution of Hyperreninemia, Secondary Hyperaldosteronism, and Hypokalemia With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy in a Patient With Pancreatic Neuroendocrine Tumor
Authors: William Makis, Karey McCann, Terence A. Riauka, Alexander J.B. McEwan
Journal: Clinical Nuclear Medicine (2015)

A 54-year-old woman presented with a history of nausea, vomiting, diarrhea, and recurrent episodes of severe hypokalemia requiring hospitalization. Imaging revealed a pancreatic mass with liver metastases, histologically confirmed to be a neuroendocrine tumor. Elevated active renin and aldosterone levels were identified, and the patient was treated with 4 induction cycles of Lu-DOTATATE, which resolved the diarrhea, nausea, and hypokalemia, and normalized the renin and aldosterone levels. After 3 additional maintenance Lu-DOTATATE treatments, the pancreatic tumor had decreased in size, was deemed operable, and was resected. She remains on maintenance Lu-DOTATATE therapy with progression-free survival of 45 months thus far.